Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer

Salomonsson, Annette LU ; Micke, Patrick ; Mattsson, Johanna S.M. ; La Fleur, Linnea ; Isaksson, Johan ; Jönsson, Mats LU ; Nodin, Björn LU ; Botling, Johan ; Uhlén, Mathias and Jirström, Karin LU orcid , et al. (2020) In Cancer Medicine 9(15). p.5609-5619
Abstract

Aims: High expression of the RNA-binding motif protein 3 (RBM3) correlates with improved prognosis in several major types of cancer. The aim of the present study was to examine the prognostic value of RBM3 protein and mRNA expression in non-small cell lung cancer (NSCLC). Methods and results: Immunohistochemical expression of RBM3 was evaluated in surgically treated NSCLC from two independent patient populations (n = 213 and n = 306). Staining patterns were correlated with clinicopathological parameters, overall survival (OS), and recurrence-free interval (RFI). Cases with high nuclear RBM3 protein expression had a prolonged 5-year OS in both cohorts when analyzing adenocarcinomas separately (P =.02 and P =.01). RBM3 remained an... (More)

Aims: High expression of the RNA-binding motif protein 3 (RBM3) correlates with improved prognosis in several major types of cancer. The aim of the present study was to examine the prognostic value of RBM3 protein and mRNA expression in non-small cell lung cancer (NSCLC). Methods and results: Immunohistochemical expression of RBM3 was evaluated in surgically treated NSCLC from two independent patient populations (n = 213 and n = 306). Staining patterns were correlated with clinicopathological parameters, overall survival (OS), and recurrence-free interval (RFI). Cases with high nuclear RBM3 protein expression had a prolonged 5-year OS in both cohorts when analyzing adenocarcinomas separately (P =.02 and P =.01). RBM3 remained an independent prognostic factor for OS in multivariable analysis of cohort I (HR 0.44, 95% CI 0.21-0.90) and for RFI in cohort II (HR 0.38, 95% CI 0.22-0.74). In squamous cell carcinoma, there was instead an insignificant association to poor prognosis. Also, the expression levels of RBM3 mRNA were investigated in 2087 lung adenocarcinomas and 899 squamous cell carcinomas assembled from 13 and 8 public gene expression microarray datasets, respectively. The RBM3 mRNA levels were not clearly associated with patient outcome in either adenocarcinomas or squamous cell carcinomas. Conclusions: The results from this study support that high protein expression of RBM3 is linked to improved outcome in lung adenocarcinoma.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarker, gene expression, immunohistochemistry, survival, tissue microarray
in
Cancer Medicine
volume
9
issue
15
pages
11 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85085761152
  • pmid:32491279
ISSN
2045-7634
DOI
10.1002/cam4.3149
language
English
LU publication?
yes
id
e682fcb4-f6c9-4d83-91ab-dac7443b7941
date added to LUP
2021-01-08 14:07:24
date last changed
2024-05-01 23:55:16
@article{e682fcb4-f6c9-4d83-91ab-dac7443b7941,
  abstract     = {{<p>Aims: High expression of the RNA-binding motif protein 3 (RBM3) correlates with improved prognosis in several major types of cancer. The aim of the present study was to examine the prognostic value of RBM3 protein and mRNA expression in non-small cell lung cancer (NSCLC). Methods and results: Immunohistochemical expression of RBM3 was evaluated in surgically treated NSCLC from two independent patient populations (n = 213 and n = 306). Staining patterns were correlated with clinicopathological parameters, overall survival (OS), and recurrence-free interval (RFI). Cases with high nuclear RBM3 protein expression had a prolonged 5-year OS in both cohorts when analyzing adenocarcinomas separately (P =.02 and P =.01). RBM3 remained an independent prognostic factor for OS in multivariable analysis of cohort I (HR 0.44, 95% CI 0.21-0.90) and for RFI in cohort II (HR 0.38, 95% CI 0.22-0.74). In squamous cell carcinoma, there was instead an insignificant association to poor prognosis. Also, the expression levels of RBM3 mRNA were investigated in 2087 lung adenocarcinomas and 899 squamous cell carcinomas assembled from 13 and 8 public gene expression microarray datasets, respectively. The RBM3 mRNA levels were not clearly associated with patient outcome in either adenocarcinomas or squamous cell carcinomas. Conclusions: The results from this study support that high protein expression of RBM3 is linked to improved outcome in lung adenocarcinoma.</p>}},
  author       = {{Salomonsson, Annette and Micke, Patrick and Mattsson, Johanna S.M. and La Fleur, Linnea and Isaksson, Johan and Jönsson, Mats and Nodin, Björn and Botling, Johan and Uhlén, Mathias and Jirström, Karin and Staaf, Johan and Planck, Maria and Brunnström, Hans}},
  issn         = {{2045-7634}},
  keywords     = {{biomarker; gene expression; immunohistochemistry; survival; tissue microarray}},
  language     = {{eng}},
  number       = {{15}},
  pages        = {{5609--5619}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Cancer Medicine}},
  title        = {{Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer}},
  url          = {{http://dx.doi.org/10.1002/cam4.3149}},
  doi          = {{10.1002/cam4.3149}},
  volume       = {{9}},
  year         = {{2020}},
}